ArticleClinical lung cancer2026
Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.
Article in Clinical lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeEpidermal growth factor receptor (EGFR) mutations occur in approximately 20%-30% of nonsmall cell lung cancers (NSCLC). Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, irreversibly binds to EGFR mutations T790M, L858R, and exon 19 deletion. In clinical trials, osimertinib demonstrated superior PFS benefit in NSCLC. However, generalizability is limited by the underrepresentation of Black patients. This study aims to evaluate the efficacy and safety of osimertinib in Black patients compared to non-Black patients. PATIENTS AND
methodsThis is a single-center, retrospective chart review of adult patients with EGFR-mutated NSCLC prescribed osimertinib in the adjuvant or metastatic setting as monotherapy or with chemotherapy from January 1, 2018, to May 31, 2024. The primary objective is real-world PFS (rwPFS). Secondary objectives include OS and characterization of osimertinib safety through ADRs, dose reductions, and medication discontinuation.
resultsA total of 152 patients with EGFR-mutated NSCLC were identified for study inclusion: 48 self-identified Black and 104 self-identified non-Black patients. The median rwPFS was 16.7 months in the Black patient group and 15 months in the non-Black patient group (HR for disease progression or death, 0.80; 95% CI, 0.51-1.21; P = .273). Median OS was 65 months in the Black group versus 37.8 months in the non-Black group (HR for death, 0.85; 95% CI, 0.46-1.49; P = .544). No significant differences were seen in osimertinib safety between groups with 95.8% of Black patients and 99% of non-Black patients experiencing an ADR (P = .235).
conclusionsBlack patients receiving osimertinib for EGFR-mutated NSCLC had similar outcomes compared to non-black patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.